Literature DB >> 18716009

Impact of clinical variables on Borrelia burgdorferi-specific antibody seropositivity in acute-phase sera from patients in North America with culture-confirmed early Lyme disease.

Gary P Wormser1, John Nowakowski, Robert B Nadelman, Paul Visintainer, Andrew Levin, Maria E Aguero-Rosenfeld.   

Abstract

Erythema migrans, the most common manifestation of Lyme disease, has been associated with highly variable rates of seropositivity for antibodies to Borrelia burgdorferi. Differences in the sensitivities of serologic assays for the detection of these antibodies, however, may not be the only or even the primary explanation for this observation. We investigated the impacts of four clinical variables on seropositivity--the duration of erythema migrans, the presence of single versus multiple skin lesions, and the gender and age of the patient. In this analysis, three different serologic tests were performed on acute-phase sera from 175 untreated patients with culture-confirmed erythema migrans: the C6 single-peptide enzyme-linked immunosorbent assay (ELISA), a commercially available ELISA in which a whole-cell sonicate of B. burgdorferi was the antigen, and a two-tier procedure. Irrespective of the serologic test performed, the results showed that seropositivity rates increased with the duration of the erythema migrans for patients with single lesions (P < 0.001) but not for those with multiple skin lesions. The variability in seropositivity rates was greatest for the two-tier testing strategy, with a >6-fold-higher rate of seropositivity among patients with a single lesion of 22- to 30-day duration than among those whose skin lesion was of 1- to 7-day duration (85.7 versus 14.1%; P < 0.001). Rates of seropositivity by each of the testing methods were also significantly higher for patients with multiple skin lesions than for those with single lesions (P < 0.001). In contrast, seropositivity rates were not affected by either the gender or the age of the patient. Thus, in patients with erythema migrans, certain clinical variables such as the duration and number of skin lesions had a profound impact on seropositivity rates, irrespective of the serologic assay performed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18716009      PMCID: PMC2565926          DOI: 10.1128/CVI.00109-08

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  13 in total

1.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

2.  Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1995-08-11       Impact factor: 17.586

3.  Serodiagnosis in early Lyme disease.

Authors:  M E Aguero-Rosenfeld; J Nowakowski; D F McKenna; C A Carbonaro; G P Wormser
Journal:  J Clin Microbiol       Date:  1993-12       Impact factor: 5.948

4.  Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease.

Authors:  G P Wormser; D Liveris; J Nowakowski; R B Nadelman; L F Cavaliere; D McKenna; D Holmgren; I Schwartz
Journal:  J Infect Dis       Date:  1999-09       Impact factor: 5.226

5.  Human antibody responses to VlsE antigenic variation protein of Borrelia burgdorferi.

Authors:  M B Lawrenz; J M Hardham; R T Owens; J Nowakowski; A C Steere; G P Wormser; S J Norris
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

6.  Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE.

Authors:  F T Liang; A C Steere; A R Marques; B J Johnson; J N Miller; M T Philipp
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

Review 7.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

8.  Paradigm Burgenland: risk of Borrelia burgdorferi sensu lato infection indicated by variable seroprevalence rates in hunters.

Authors:  Emel Cetin; Mahtab Sotoudeh; Herbert Auer; Gerold Stanek
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

9.  Comparison of four immunoserologic assays for detection of antibodies to Borrelia burgdorferi in patients with culture-positive erythema migrans.

Authors:  P D Mitchell; K D Reed; T L Aspeslet; M F Vandermause; J W Melski
Journal:  J Clin Microbiol       Date:  1994-08       Impact factor: 5.948

10.  Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates.

Authors:  Rendi Murphree Bacon; Brad J Biggerstaff; Martin E Schriefer; Robert D Gilmore; Mario T Philipp; Allen C Steere; Gary P Wormser; Adriana R Marques; Barbara J B Johnson
Journal:  J Infect Dis       Date:  2003-04-02       Impact factor: 5.226

View more
  18 in total

Review 1.  Laboratory diagnosis of Lyme disease: advances and challenges.

Authors:  Adriana R Marques
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

2.  Evaluation of Modified 2-Tiered Serodiagnostic Testing Algorithms for Early Lyme Disease.

Authors:  John A Branda; Klemen Strle; Lise E Nigrovic; Paul M Lantos; Timothy J Lepore; Nitin S Damle; Mary Jane Ferraro; Allen C Steere
Journal:  Clin Infect Dis       Date:  2017-04-15       Impact factor: 9.079

3.  Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis.

Authors:  Jameson T Crowley; Klemen Strle; Elise E Drouin; Annalisa Pianta; Sheila L Arvikar; Qi Wang; Catherine E Costello; Allen C Steere
Journal:  J Autoimmun       Date:  2016-02-26       Impact factor: 7.094

4.  Lyme disease.

Authors:  Eugene D Shapiro
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

5.  Characteristics of seroconversion and implications for diagnosis of post-treatment Lyme disease syndrome: acute and convalescent serology among a prospective cohort of early Lyme disease patients.

Authors:  Alison W Rebman; Lauren A Crowder; Allison Kirkpatrick; John N Aucott
Journal:  Clin Rheumatol       Date:  2014-06-13       Impact factor: 2.980

Review 6.  Clinical practice. Lyme disease.

Authors:  Eugene D Shapiro
Journal:  N Engl J Med       Date:  2014-05-01       Impact factor: 91.245

7.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

Review 8.  Diagnosis, Treatment, and Prevention of Lyme Disease, Human Granulocytic Anaplasmosis, and Babesiosis: A Review.

Authors:  Edgar Sanchez; Edouard Vannier; Gary P Wormser; Linden T Hu
Journal:  JAMA       Date:  2016-04-26       Impact factor: 56.272

9.  Revisiting the Lyme Disease Serodiagnostic Algorithm: the Momentum Gathers.

Authors:  Adriana R Marques
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

10.  Lyme disease with erythema migrans presenting concurrently with optic nerve perineuritis and abducens nerve palsy.

Authors:  Michael S Lundin; Sherri L Sandel; Corina M Suciu; Debra A Spicehandler
Journal:  BMJ Case Rep       Date:  2020-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.